

# Meningococcal (A, C, W, Y) Vaccine

<b>Vaccine Description</b>	<ul style="list-style-type: none"> <li>• Brands: Menveo® (MenACWY-CRM) and MenQuadfi® (MenACWY-TT)</li> <li>• Inactivated, bacterial polysaccharide conjugate</li> <li>• See package insert</li> </ul>
<b>Dose &amp; Route</b>	<ul style="list-style-type: none"> <li>• Dose: 0.5 mL</li> <li>• Route: IM (Menveo® and MenQuadfi®) - (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy)</li> <li>• See package insert</li> </ul>
<b>Indications</b>	<ul style="list-style-type: none"> <li>• U.S. military basic trainees</li> <li>• Deploying personnel per CCMD guidance</li> <li>• Children at the 11-12 year of age visit or at subsequent visit</li> <li>• People who might be infected during an outbreak of certain types of meningococcal disease</li> <li>• Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as sub-Saharan Africa</li> <li>• Anyone who has a non-functioning spleen or whose spleen has been removed (asplenia)</li> <li>• Anyone who has terminal complement component deficiency (an immune system disorder)</li> <li>• Persons receiving a complement inhibitor (e.g., eculizumab; [Soliris])</li> <li>• People at occupational risk</li> <li>• College freshmen, especially those who live in dormitories</li> <li>• People with HIV infection</li> </ul>
<b>Administration Schedule</b>	<ul style="list-style-type: none"> <li>• Single dose for most adults</li> <li>• Two doses, 2 months apart, for adults at high risk; e.g., HIV infection, asplenia, complement component deficiency</li> <li>• Menveo®: Single dose vial is licensed for 10-55 years, 2 vial presentation is licensed for 2mo-55 years.</li> <li>• MenQuadfi® is licensed for 2 years and older</li> <li>• Individuals 56 years or older who are recommended meningococcal vaccination can receive either meningococcal conjugate vaccine (ACIP)</li> </ul>
<b>Booster</b> (Menveo® and MenQuadFi®)	<ul style="list-style-type: none"> <li>• Menveo® and MenQuadfi®:</li> <li>• A booster dose is recommended for people 19 through 21 years of age who are at risk (above) or first-year college students living in residence halls or a military recruit, if previous dose given before 16 years of age</li> <li>• People with persistent risk need booster every 5 years for as long as risk is present (this includes those with risk due to travel, persistent complement component deficiency, or functional or anatomic asplenia)</li> </ul>

# Meningococcal (A, C, W, Y) Vaccine

(Continued)

<b>Contraindications</b>	<ul style="list-style-type: none"> <li>• Serious allergic reaction to prior dose or vaccine component</li> <li>• Moderate or severe illness (temporary waiver)</li> <li>• Menveo: severe allergic reaction to any diphtheria toxoid or CRM<sub>197</sub> containing vaccine.</li> <li>• MenQuadfi: severe allergic reaction to a tetanus toxoid-containing vaccine</li> </ul>
<b>Special Considerations</b>	<ul style="list-style-type: none"> <li>• Menveo® and MenQuadfi® have not been widely studied in pregnant or lactating women and should be given only if clearly indicated.</li> <li>• Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease can receive either MenACWY conjugate vaccine. This includes:             <ul style="list-style-type: none"> <li>◦ Meningococcal vaccine-naïve persons ≥56 years who require only a single dose of vaccine (e.g. travelers and persons at risk as a result of a community outbreak)</li> <li>◦ Persons who are recommended for revaccination or for whom multiple doses are anticipated (e.g., persons with asplenia, HIV, and microbiologists)</li> </ul> </li> <li>• **Penbraya® (MenACWY-TT/MenB-FHbp) is licensed as a 2-dose series given 6 months apart, for individuals aged 10-25 years. Pfizer's Penbraya® vaccine may be used when both MenACWY and MenB are indicated at the same visit for:             <ul style="list-style-type: none"> <li>◦ Healthy individuals age 16 through 23 years (routine schedule) when shared clinical decision-making (SCDM) favors administration of MenB vaccination (requires order from privileged provider).</li> <li>◦ Individuals age 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines</li> <li>◦ The MenB component of Penbraya® is the MenB vaccine Trumenba®. As Trumenba® and Bexsero® are not interchangeable, a primary series and any future MenB booster doses must be of the same brand.</li> </ul> </li> <li>• See Storage and Handling Section</li> </ul>
<ul style="list-style-type: none"> <li>• VIS: <a href="http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html</a></li> <li>• Standing Orders: <a href="http://www.health.mil/standingorders">www.health.mil/standingorders</a></li> <li>• Pregnancy registry for Menactra®: 1-800-822-2463 (Sanofi Pasteur); Pregnancy registry for Menveo®: 1-877-311-8972 (Novartis); also notify DHA- IHD</li> <li>• Additional education may be found at <a href="http://www.health.mil/meningococcal">www.health.mil/meningococcal</a></li> </ul>	